Прогностическое значение маркеров оксидативного стресса у больных стабильной ишемической болезнью сердца

Список литературы

1. Адамов А.К., Павлова Ю. П. Антимикробное действие системы ксантиноксидаза ксантин на возбудителя холеры. Журн микроб, эпидем. и иммунол. 1990 № 8 с.З.
2. Артамошина Н.Е., Белая О. Л., Радзевич A3., Куроптева 31 В., Байдер Л. М. Коррекция антиоксидантного статуса при лечении статинами у больных, ишемической болезнью сердца. Клиническая медицина 2009 (11): 25−9.
3. Бурлакова< Е.Б. и др. Роль липидов в процессе передачи информации в клетке.// Биохимия липидов и их роль в обмене веществ. 1981. С.23−24:
4. Владимиров Ю.А., Арчаков А. И. ПОЛ в биологических мембранах. М.: Наука, 1972. 218 с.
5. Голиков А.П., Полумисков В. Ю., Бойцов С. А., Михин В. П. Свободнорадикальное окисление и сердечно-сосудистая патология: коррекция антиоксидантами. Лечащий врач, 2003.-N-4.-C.70−74
6. Грызунов Ю.А. и Добрецов Г.Е. «Альбумин сыворотки крови в клинической медицине» Книга 2, стр. 20−27, 28−51, 178−182, 214−218, «ГЭОТАР», Москва, 1998
7. Давиденкова Е.Ф. Миелопероксидаза нейтрофилов и ее возможное участие в процессе перекисного окисления липидов. Клин. Мед. 1989 № 6 — с. 51.
8. Диагностика и лечение стабильной стенокардии (Рекомендации ВНОК). Кардиоваскулярная терапия и профилактика. 2008- 7 (6). Приложение 4.
9. Дубинина Е.Е., Бурмистров С. О., Ходов Д. А., Поротов Г. Е. Окислительная модификация белков сыворотки крови человека, метод ее определения. Вопросы медицинской химии. 1995. Т. 41. № 1. С. 24−26.
10. Егоров Д. Ю., Козлов A.B. Природа продуктов ПОЛ, определяемых в сыворотке крови по реакции с 2-тиобарбитуровой кислотой. М., 1988, с.3−13
11. Зенков Н.К., Ланкин В. З., Меньщикова Е. Б. Окислительный стресс: биохимический w патофизиологический аспекты. М.:МАИК «Наука/Интерпериодика», 2001, 343 с.
12. Климов А.Н., Никульчева Н. Г. Липиды, липопротеиды и атеросклероз. СПб.: Изд-во «Питер», 1995. — 297с.
13. Коган А.Х., Кудрин А. Н., Николаев С. М. и др. (1991) Открытие в СССР, с.31−33.
14. Коган А.Х., Лосев Н. И., Бирюков Ю. В., Сыркин А. Л., Погромов А. П. и др. О роли легких в регуляции генерации АФК лейкоцитами в норме и патологии. Патофизиол. и экспер. терапия. 1991. — № 1. — С.46−50.
15. Коган А.Х., Погромов А. П. АФК, лейкоциты и патогенез гастродуоденальной язвенной болезни. 1991. С. 27.
16. B., Каминный А. И., Тихазе A. К., Агеев Ф. Т. Духарчук В. В., Беленков Ю. Н. Окислительный стресс при атеросклерозе и диабете. Бюллетень экспериментальной биологии и медицины 2005- 140: 41−3.
17. Ланкин В.З., Тихазе А. К., Беленков Ю. Н. Свободно-радикальные процессы при заболеваниях сердечно-сосудистой системы. Кардиология. 2000. № 7. с. 48−61.
18. Оганов Р.Г., Деев А. Д., Жуковский Г. С. и др. Влияние курения на смертность от хронических неинфекционных заболеваний по результатам^ проспективного исследования. Профилактика заболеваний и укрепление здоровья. 1998. № 3.1. C.13−15.
19. Родоман Г. В., Шалаева Т. И., Добрецов Г. Е., Коротаев АЛ. Бюлл.эксперим.биол. и мед. 1999. -Т.128. № 12. — С.660−662.
20. Сергиенко В.И., Азизова O.A., Халилов Э. М., Владимиров Ю. А. и соавт. Структурно-фукциональные изменения тромбоцитов при экспериментальном атеросклерозе. Бюлл. экспер. биол. и мед. 1984. — № 2. — С. 149−152.
21. Сергиенко В.И., Мартынов А. К., Васильев Ю. Б., Гринберг В. А. и соавт. Непрямое электрохимическое окисление с использованием переносчиков активного кислорода в моделировании детоксицирующей функции печени. Вопр. мед. химии. 1990. № 36(3). С.28−32.
22. Ситникова М. Ю., Иванов С. Г., Хмельницкая К. А'. Плейотропные эффекты в-адреноблокаторов1 в терапии сердечно-сосудистых заболеваний: влияние на перекисное окисление липидов, свойства эндотелия и эволюцию атеросклероза. «Кардиология» № 6, 2009: 61−66
23. Стукова Н.Ю. Изменения функциональной активности кислородзависимых бактерицидных систем фагоцитов при взаимодействии с чумным микробом и его антигенами. Автореф. дис. канд. мед. наук Саратов -1991.
24. Тертов В.В. Множественно-модифицированные липопротеиды, низкой плотности, циркулирующие в крови: человека- Ангиология и сосудистая хирургия. 1999 г. том 5, стр.218−240.
25. Торховская Т.И., Горбатенкова Е. А., Дудаев В. А., Чеснокова Я. М. и др. Холестерин-акцепторные, свойства липопротеидов высокой плотности убольных ИБС по отношению к мембранам эритроцитов. Вопр. Мед. Хим. 1986. № 26 (2). С.101−104.
26. Федин А. И. Оксидантный стресс и применение антиоксидантов в неврологии. АтмосферА*. Нервные болезни. 1.2002. стр. 15−18.
27. Шальнова С.А., Оганов Р. Г., Деев А. Д. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001. № 2. С.3−7.
28. Шинкаренко Н. В- Химическая основа поведения синглетного кислорода в организме человека. Вопр. Мед. Химии. 1986. Т.5. С. 2−7.
29. Acuff RV, Thedford SS, Hidiroglou NN et al. Relative bioavailability of RRR- and all-rac-alpha-tocopheryl acetate in humans: studies using deuterated: compounds. Am J Clin Nutr 1994- 60: 397−402
30. Agarwal R. Smoking, oxidative stress and inflammation: impact on resting energy expenditure in diabetes nephropathy. BMC Nephrology 2005−6:13.
31. Akcay A, Acar G, Kurutas E, Sokmen A, Atli Y, Nacar AB, Tuncer C. Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Turk Kardiyol Dern Ars. 2010 Jun- 38(4):244−9.
32. Alaupovic P. Apolipoproteins and lipoproteins. Atherosclerosis. l971−13:141−159.
33. Alexander R. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995- 25: 155−161.
34. Argmann C., Edwards J., Sawyez C., Neil C. et al. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCAl-mediated cholesterol efflux. 3 Biol Chem. 2005- 280 (10): 22 122 221.
35. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S. et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest. 1998- 101(10): 1581−1590.
36. Azizova O., Vakhrusheva T., Dremina E., Sharov V. Role of lipoprotein bound copper ions in lipid peroxidation of low and high density lipoproteins. Biofizika 1997−42 (3): 662−670.
37. Bassenge E, Schneider HT, Daiber A. Oxidative stress and cardiovascular diseases. Dtsch Med Wochenschr. 2005 Dec 16- 130(50):2904−9:
38. Belch JJ- Chopra M- Hutchison S- Lorimer R- Sturrock RD- Forbes CD- Smith WE. Free radical pathology in chronic arterial disease. Free Radic Biol Med. 1989- 6(4): 375−8.
39. Bellavite P., Berton B. et al. The superoxidoforming enzymatic system of phagocytes. Free Radical Biology et Medicine. 1988- 4: 225−261.
40. Berkenboom G. Unstable atheromatous plaque. Physiopathology and therapeutic approach to coronary insufficiency. Rev Med Brux. 2001 Dec- 22(6):497−502.
41. Berliner J.A. et al. Atherosclerosis: Basic mechanisms oxidation, inflammation, and genetics. Circulation 91: 2488−2496, 1995.
42. Berliner J.A., Heinnecke J.W. The .role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996- 20: 707−727.
43. Berliner JA, Watson AD. A Role for Oxidized Phospholipids in Atherosclerosis N Engl J Med 2005- 353:9−11.
44. Bernhard D., Wang X.L. Smoking, oxidative stress and cardiovascular diseases-do anti-oxidative therapies fail? Curr Med Chem. 2007- 14(16): 1703−12.
45. Bjorkerud B. Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts. Arteriocler Thromb Vase Biol. 1996- 16(5): 416 424.
46. Blake GJ, Ridker PM. Are statins anti-inflammatory? Curr Control Trials Cardiovasc Med. 2000- 1(3):161−165.
47. Blake GJ, Ridker PM. Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application. Ital Heart J. 2001 Nov- 2(ll):796−800.
48. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with, antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000- 356: 1213−1218.
49. Brown WV. Impact of dyslipidaemia. Lessons from clinical trials. Pharmacoeconomics. 1998- 14 Suppl 3: 1−9.
50. Cattaneo D, Remuzzi G. Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. J Ren Nutr. 2005 Jan- 15 (l):71−6.
51. Ceconi C, Boraso A, Cargnoni A, Ferrari R Oxidative stress in cardiovascular disease: myth or fact? Arch Biochem Biophys. 2003 Dec 15--420(2):217−21.
52. Chalmers A. Smoking and oxidative stress. Letter to the Editor. Amer J Clin Nutrition 1999- 69: 572.
53. Champlain J, Wu R, Girouard H, Karas M, EL Midaoui A, Laplante MA, Wu L. Oxidative stress in hypertension. Clin Exp Hypertens 2004- 26: 593−601
54. Chance B, Sies H, and Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev-1979- 59: 527−605.
55. Chantal Capeillere-Blandin, Valerie Gausson et al. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochimica et Biophysica Acta, 2004, 91−102
56. Chen K, Thomas SR, Keaney JF Jr. Beyond LDL oxidation: ROS in vascular signal transduction. Free RadicBiol Med 35: 117−132, 2003.
57. Chen Ya-Fei, Li Pin-Lan, Zou Ai-Ping. Effect of Hyperhomocysteinemia on Plasma or Tissue Adenosine Levels and Renal Function. Circulation 2002- 106: 1275.
58. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection. Study: preliminary results. Int J Clin Pract. 2002 Jan-Feb-56(l):53−6.
59. Cominacini L, Garbin U, Pastorino AM et al. Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease. Ather. 1993 feb.- 99 (1): 63−70.
60. Cyrus T, Yao Y, Rokach 3, Tang LX, Pratico D. Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-deficient mice with established vascular lesions. Circulation. 2003 Feb 4- 107(4):521−523.103.
61. Davies K. 3.A. Protein damage and degradation by oxygen radicals. I. general aspects. 1 Biol. Chem. 1987. Vol. 262, N 20. P. 9895−9901.
62. Dean J., Jones C., Hutchinson S. Hyperinsulinemia and microvascular angina («syndrome X»). Lancet 1991. — Vol. 337. — P. 456−457.
63. Dean M., Hamon Y., Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 2001- 42:1007−1017.
64. Dormandy T. L. An approach to free radicals. Lancet 1983- 2: 1010−1014.
65. Dormandy T. L. Free-radical pathology and medicine. J.R.Coll.Physiciens Lond. 1989- 23(4):221−227.
66. Erdamar H, Sen N, Tavil Y, Yazici HU, Turfan M, Poyraz F, Topai S, Okuyan H, Cemri M, Cengel A. The effect of nebivolol treatment on oxidative stress andantioxidant status in patients with cardiac syndrome-X. Coron Artery Dis. 2009 May- 20(3):238−4.
67. Ernster L. Facts and ideas about the function of coenzyme QIO in the Mitochondria. In: K. Folkers, Y. Yamamura (eds.). Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier 1977- 15 -18.
68. Escobedo L.G., Caspersen C.Y. Risk factors for sudden coronary death in the United States. Epidemiology. 1997. V.8. P. 175−180.
69. Esterbauer H, Gebicki 3, Puhl H et al. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992- 13: 341−90.
70. Esterbauer H., Waeg G., Puhl H. Lipid peroxidation and its role in atherosclerosis. British Medical Bulletin. 1993. Vol. 49. P. 566−576.
71. Fransis G.A. HDL oxidation- in vitro susceptibility and potential in vivo consequences Biochim. Biophys. Acta. 2000- 1483 (2): 217−35.
72. Fridovich J. Oxygen and Living Process. Interdiscipline Approach. New York. 1981- 1: 250−272.
73. Gerschman R, Gilbert D, Nye SW, Dwyer P, and Fenn WO. Oxygen poisoning and X-irradiation: a mechanism in common. Science 119: 623−626, 1954.
74. Gesquiere L., Loreau N., Blache D. Impaired cellular Ch efflux by oxisterol-enriched HDL. Free Radical. Biol. Med. 1997- 232: 541−547.
75. Gey KF, Ducimetiere P, Evans A, Amouyel P, Arveiler D, Ferrieres 3, Luc G, Kee F, Bingham A, Yarnell 3, Cambien F. Low plasma retinol predicts coronary events inhealthy middle-aged men: the PRIME Study. Atherosclerosis. 2010 Jan-208(l):270−4.
76. Gey KF, Stahelin HB, Eichholzer M. Poor plasma status of carotene and vitamin C is associated with higher mortality from ischemic heart disease and stroke: Basel Prospective Study. Clin Investig. 1993 Jan- 71(l):3−6.
77. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999: 354: 447−55.
78. Glavind J., Hartmann S., Clemmensen J. et al. Studies on the role of lipid peroxides in human pathology. Acta Pathol Microbiol Scand 1952- 30: 1−6.
79. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707−714, 1977.
80. Grainger D.J., Kirschenlohr M., Metcalfe J.C., Weissberg P.L., Wade O.P., Lawn R.M. Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science. 1993- 260:1655—8.
81. Griendling KK, FitzGerald, GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation. 2003, Oct 28- 108(17): 2034−40.
82. Grundy SM. Cholesterol and coronary heart disease. Future directions. JAMA. 1990 Dec 19- 264 (23): 3053−9.
83. Hallivel B. Gutteridge J.M.C., Cross C.E. Free radicals, antioxidants and human disease: where are we now? J.Lab.Clin.Med. 1992- 119 (6): 598−620.
84. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. New York: Oxford Univ. Press, 1999.
85. Halliwell B. Albumin—An important extracellular antioxidant? Biochem. Pharmacol., 1988, v.37, p. 569−571.
86. Hankey G. Eikelboom Homocysteine and vascular disease. Lancet. 1999. V. 354. P. 407−412.
87. Hansson GK. Inflammatory mechanisms in atherosclerosis. X Thromb Haemost. 2009 Jul- 7 Suppl 1:328−31.
88. Heinecke J.W. Mass spectrometry quantification of amino acid oxidation products in • proteins: insights into pathways that promote LDL oxidation in the human artery wall. FASEB J 13: 1113−1120, 1999.
89. Henry P.D. Atherogenesis, calcium and calcium antagonists. Am J Cardiol. 1990 Dec 18- 66 (21): 31−61.
90. Hessler J.R., A.L. Robertson, G.M., Chisolm. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979, 32: 213−229.
91. Higashi Y, Chayama K, Yoshizumi M. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress. Curr Med Chem Cardiovasc Hematol Agents. 2005 Apr- 3(2): 133−48.
92. Holvoet P, Van Cleemput J, Collen D, Vanhaecke J. Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vase Biol. 2000 Mar- 20(3):698−702.
93. Hubert H., Fienlied M., McNamara P., Castelli W. Obesity as an independent risk factor for cardiovascular disease: a 26 year follow-up of participants in the Framingham Heart Study. Circulation: 1983. Vol. 67. P. 5−15.
94. Hunninghake D. LDL-cholesterol as a determinant of coronary heart disease. Clin Ther. 1990 Sep-Oct- 12(5): 370−5.
95. Iuliano L., Signore A., Vallabajosula S., Colavita A. R., Camastra C., Ronga G., Alessandri C., Sbarigia E., Fiorani P., Violi F. Preparation and biodistribution of technetium-99m labeled oxidized LDL in man. Atherosclerosis 1996- 126:131−141.
96. Jacobsen D.W. Hyperhomocysteinemia and Oxidative, Stress. Arteriosclerosis, Thrombosis, and Vascular Biology 2000- 20: 1182.
97. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis. 2002 May- 162(l):221−5.
98. Kannel W.B., McGee D.L., Castelli W.P. Latest perspectives on cigarette smoking and cardiovascular disease: the Framingham study. J. Cadiac. Rehabil. 1984. V.4. P. 267−277.
99. Keys A. Seven Countries: a multivariate analysis of death and coronary heart disease. Cambridge, MA, Harvard University Press, 1980.
100. Knekt P., Reunanen A., Jarviven R., Seppanen R., Helicvaara M., Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am. J. Epidem. 1994- 139: 1180−1189.
101. Kragh-Hansen U. Structure and ligand binding properties of human serum albumin. Dan. Med. Bull. 1990. — Vol. 37, N 1. — P. 57−84.
102. Krauss R.M., Winston M., Fletcher B.J., Grundy S.M. Obesity: impact on cardiovascular disease AHA conference proceedings. Circulation. 1998. V.98: 14 721 476.
103. Kuklinski B, Weissenbacher E, Fahnrich A. Coenzyme QIO and antioxidants in acute myocardial infarction. Mol Aspects Med. 1994- 15 Suppl: S143−7.
104. Kuzuya M, Yamada K, Hayashi T, Funaki C, Natio M, Asai K, Kuzuya F et al. Role of lipoprotein-copper complex in copper catalyzed peroxidation of low-density lipoprotein. Biochim Biophys Acta 1992- 1123(3): 334−341.
105. Lafont AM, Chai YC, ComhilPF et al. Effect of alpha-tocopherol on restenosis after angioplasty in a model of experimental atherosclerosis. J Clin Invest 1995- 95: 1018−1025.
106. Lakshmi SV, Padmaja G, Kuppusamy P, Kutala VK. Oxidative stress in cardiovascular disease. Indian 3 Biochem Biophyis. 2009 Dec- 46 (6):421−40.
107. Lam T.H., He Y., Passive smoking and coronary heart disease: a brief review. Clin. Exp. Pharmacol. Physiol. 1997. V. 24. P. 993−996.
108. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 104: R25-R31, 1999.
109. Lee RT., Libby P. The unstable antheroma. Arterioscl Thromb Vase Biol. 1997: 17: 1859−1867
110. Levine R. L., Garland D., Oliver C. N. et al. Determination of carbonyl content in oxidatively modified proteins.// Meth. Enzymol. 1990. Vol. 186. P. 464—478.
111. Li 3, Sun YM, Wang LF, Li ZQ, Pan W, Cao HY. Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. Clin Cardiol. 2010 Apr- 33(4):222−7.
112. Li YC, Ge LS, Yang PL, Tang JF, Lin JF, Chen P, Guan XQ. Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction. Eur J Pharmacol. 2010 Aug 25- 640(l-3):112−6.
113. Loscalzo J. The Oxidant Stress of Hyperhomocyst (e)inemia. J Clin Invest 1996- 98 (1): 5−7.
114. Loscalzo J., Weinfeld M., Fless G.M., Scanu A.M. Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990- 10:240—5.
115. Majors A., Ehrhart A., Pezacka E. Homocysteine as a Risk Factor for Vascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology 1997- 17: 2074−2081.
116. McCord JM. Oxygen-derived free radicals in postishemic tissue injury. N Engl J Med 312: 159−163, 1985.
117. Michael Schrader, H. Dariush Fahimi. Peroxisomes and oxidative stress. Biochimica et Biophysica Acta 2006 Dec.- 1763 (12): 1755−1767.
118. Mohazzab K M, Wolin M S. Sites of superoxide anion production detected by lucigenin in calf-pulmonary artery smooth-muscle. Am J Physiol Lung Cell MolPhysiol 267: L815-L822, 1994.
119. Morimoto Y, Kureishi-Bando Y, Murohara T. Calcium antagonists: current and future applications based on new evidence. Pleiotropic effects of calcium channel blockers on vascular endothelial function. Clin Calcium. 2010 Jan- 20(l):69−75.
120. MR Namazi. Cytochrome-P450 enzymes and autoimmunity: expansion of the relationship and introduction of free radicals as the link. Journal of Autoimmune Diseases -2009, 6:4.
121. Napoli C, Postiglione A, Triggisni M, Corso G, Palumbo G, Carbone V, Ruocco A, Ambrosio G. Oxidative structural modifications of LDL in homozygous familial hypercholesterolemia. Atherosclerosis 1995- 18:259−273
122. Naruszewicz M., Selinger E., Davignon J. Oxidative modification of lipoprotein (a) and the effect of beta-carotene. Metabolism 1992- 41:1215—24.
123. Nishiyama A, Nakano D, Hitomi H. Calcium antagonists: current and future applications based on new evidence. Effects of calcium channel blockers on oxidative stress. Clin Calcium. 2010 Jan- 20(l):38−44.
124. Nohl H. A novel superoxide radical generator in heart mitochondria. FEBS Letter 1993- 214: 268−273.
125. Noll G. Pathogenesis of atherosclerosis: a possible relation to infection, Atherosclerosis 1998- 140 (SI): S3-S9.
126. Nygard O., Vollset S., Refsum H. et al. Total homocysteine and cardiovascular disease. J Intern Med 1999- 246: 425−454.
127. Oliver C.N., Ahn B.W., Moerman E.J., Goldstein S, Stadtman E.R. Age-related changes in oxidized proteins. 3 Biol Chem. 1987 Apr 25- 262(12):5488−5491.
128. Ozer NK, Sirikci 0, Taha S et al. Effect of vitamin E and probucol on dietary cholesterol-induced atherosclerosis in rabbits. Free Radic Biol Med 1998- 24: 226 233.
129. Pagano PJ, Ito Y, Tornheim K, Gallop PM- Tauber AI, and Cohen RA. An NADPH oxidase superoxide-generating system in the rabbit aorta. Am J Physiol Heart CircPhysiol 268: H2274-H2280,1995.
130. Parthasarathy S., Printz D., Boyd D., Joy L. et al. Macrophage oxidation of low density lipoprotein generates a modified from recongnized by the scavenger receptor. Atherosclerosis. 1986- 6: 505−510.
131. Pennathur S., Heinecke J., Oxidative stress and endothelial dysfunction in vascular disease. Curr Diab Rep. 2007 Aug- 7 (4): 2 57−64.
132. Perna A., Castaldo P., Ingrosso D. Homocysteine, a new cardiovascular risk factor, is also a powerfuluremic toxin. J Nephrol 1999- 12: 230−240.
133. Phillips S., Thornalley P. The formation of methylglyoxal from triose phosphates. Investigation using a specificassay for methilglyoxal. Eur J Biochem 1993- 212:104—105
134. Picard S., Talussot C., Serusclat A., Ambrosio N., Berthezene F. Minimally oxidized LDL as estimated by a new method increase in plasma of type 2 diabetic patients with atherosclerosis or nephropathy. Diabetes Metab. 1996- 22(1): 25−30.
135. Piotrowski J. 1, Shah S., Alexander J. J. Mature human atherosclerotic plaque contains peroxidised phosphatidylcholine as a major lipid-peroxide. Life Sci.1996- 58:735−740.
136. Piwowar A. Advanced oxidation protein products. Part I. Mechanism of the formation, characteristics and property. Pol Merkur Lekarski.- 2010 Feb-28(164): 166−9.
137. Pollock DM. Endothelin, angiotensin, and oxidative stress in hypertension. Hypertension 2005- 45: 477.
138. Poon M., Zhang X., Dunsky K.G., Taubman M.B., Harpel P.C. Apolipoprotein (a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997- 96: 2514—9.
139. Pratico D, Tangirala RK, Rader D et al. Vitamin E suppresses iso- prostane generation in vivo and reduces atherosclerosis in Apo E- deficient mice. Nat Med 1998- 4: 1189−92.
140. Price M.J., Shah P.K. New Strategies in managing and preventing atherosclerosis: focus on HDL. Rev. Cardiovasc. Med. 2002, 3(3), 129−137.
141. Rader DJ. High-density lipoproteins and atherosclerosis. Am J Cardiol. 2002 Oct 17- 90 (8A):62i-70i.
142. Ragbir S, Farmer JA: Dysfunctional High-Density Lipoprotein and Atherosclerosis. Current atherosclerosis reports. 2010 May-27.
143. Rao V, Kiran R. Evaluation of correlation between oxidative stress and", abnormal lipid profile in coronary artery disease. 3 Cardiovasc Dis Res. 2011 Jan-2(l):57−60.
144. Rapola JM, Virtamo J, Ripatti S et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997- 349: 1715−1720.
145. Rath M., Niendorf A., Reblin T., Dietel M., Krebber H.J., Beisiegel U. Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989- 9: 579—92.
146. Riis Hansen P., Kharazmi A., Jauhianen M., Ehnholm C. Induction of oxygen free radical generation in human monocytes by lipoprotein (a). Eur J Clin Invest 1994- 24:497—9.
147. Roland Stacker and John F., Keaney Jr. Role of Oxidative Modifications in Atherosclerosis. Physiol. Rev. 2004 (84): 1381−1478.
148. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801, 1993.
149. Ross R., Glomset J., Harker L., Response to injury and atherogenesis, Am J Pathol 1977- 86: 675−684.
150. Rowley D., Halliwell B: Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds. FEBS Lett 1982- 138: 33−36.
151. Rubin SM, Sidney S, Black DM, Browner WS, Hulley SB, Cummings SR. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med. 1990 Dec 15- 113(12): 916−20.
152. Ruuge E. K, Ledenev A.N., Lakomkin V.L. et al. Free radical metabolites in myocardium during ischemia and reperfusion. Am J Physiol 1991- 261: 81−86.
153. Samokyszyn VM, Marnett ?. Hydroperoxide-dependent cooxidation of 13-cis-retinoic acid by prostaglandin H synthase. J Biol Chem 262:14 119−14 133, 1987.
154. Santini S.A., Marra G., Giardina B., Cotroneo P. et al. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes. 1997- 46: 1853−1858.
155. Sarnak M J., Wang S.R., Beck G J. et al. Homocysteine, cysteine, and B vitamins as predictors of kidney disease progression. Am J Kidney Dis 2002- 40 (5): 932 939.
156. Scanu A.M., Lawn R.M., Berg K. Lipoprotein (a) and atherosclerosis. Ann Intern Med 1991- 115: 209—18.
157. Schlienger JL, Goichot B, Pradignac A. Cholesterolemia and pathology: update Rev Med Interne. 1998 Mar- 19 (3):180−4.
158. Schroeder F., Gallegos A., Atshaves B. et al. Recent advances in membrane microdinamic: rafts, caveolae and intracellular cholesterol trafficking. ExpBiol Med. 2001- 226 (10): 873−90.
159. Shaik IH, Mehvar R. Cytochrome P450 induction by Phenobarbital exacerbates warm hepatic ischemia-reperfusion injury- in rat livers. Free Radie. Res., 2010- 44(4): 441−53.
160. Sies H. Oxidative stress: introductory remarks. In: Oxidative Stress, edited by Sies H. New York: Academic, 1985, p. 1−8.
161. Sies H. Oxidative Stress: Oxidants and Antioxidants. London: Academic, 1991.
162. Sies H. What is oxidative stress? In: Oxidative Stress and Vascular Disease, edited by Keaney JF Jr. Boston: Kluwer Academic, 2000, p. 1−8.
163. Singh RB, Neki NS, Kartikey K, Pella D, Kumar A, Niaz MA, Thakur AS. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem. 2003 Apr- 246(l-2):75−82.
164. Singh RB, Shinde SN, Chopra RK, Niaz MA, Thakur AS, Onouchi Z. Effect of coenzyme Q10 on experimental atherosclerosis and chemical composition and quality of atheroma in rabbits. Atherosclerosis. 2000 Feb- 148(2):275−82.
165. Singh S, Kumar A, Jaishankar K, Gambhir JK, Gambhir DS, Arora R. Indian Heart J. Hyperhomocyst (e)inemia presenting as multisite vascular thrombosis. 2000 Sep-Oct- 52(5):587−91.
166. Sjostrom L.V. Mortality of severely subjects. Am. J. Clin. Nutr. 1992. V.55: 516 523.
167. Stadtman E.R., Levine R.L. Protein oxidation. Annals of N.Y. Academy of Sciences. 2000. Vol. 899. P. 191−208.
168. Stadtman E.R., Oliver C.N. Metal-catalyzed oxidation of proteins. J. Biol. Chem. -1991. Vol. 266 — P. 2005−2008.
169. Stamler J., Stamler R., Neaton J.D. Blood pressure, systolic and diastolic, and cardiovascular risk: U.S. population data. Arch. Intern. Med. 1993. V.153. 598−615.
170. Stemme S., Faber B., Holm J., Wiklund 0. et al. T lymphocytes from human atherosclerosis plaque recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1995- 92: 3893−3897.
171. Stephens NG, Parsons A, Schofield PM et al. Randomised controlled trial of vitamin E in. patients with coronary disease: Cambridge Heart Antioxidant Study // Lancet 1996- 347: 781−786.
172. Sun J, Giraud DW, Moxley RA et al. Beta-carotene and alpha-tocopherol inhibit the development of atherosclerosis lesions in hypercholesterolemic rabbits. Int J Vitam Nutr Res 1997- 67- 155−163.
173. Tangirala RK, Casanada F, Miller E et al. Effect of the antioxidant N, N'-diphenyl-phenylenediamine (DPPD) on atherosclerosis in ApoE-deficient mice// Arterioscler Thromb Vase Biol 1995- 15: 1625−1630.
174. Tardif JC., Cote G., Lesperance J. et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. The New England Journal of Medicine 1997- 337(6): 365−372
175. The Multiple Risk Factor Intervention Trial Research Groop: mortality after 16 years for participants randomized to the MRFrr. Circulation. 1996. V.94. P. 945 951.
176. Toblli J, Cao G, Rivas C, Munoz M, Giani J, Dominici F, Angerosa M. Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. 3 Hypertens. 2010 May- 28(5):1007−19.
177. Tornvall P., Chirkova L., Toverud K. Native and oxidized low density lipoproteins enhance platelet aggregation in whole blood. Thromb. Res. 1999- 95 (4): 177 183.
178. Traber MG, Flsner A, Brigelius-Flohe R. Synthetic as compared with natural vitamin E is preferentially excreted as alpha-CEHC in human urine: studies using deuterated alpha-tocopheryl acetates. FEBS Lett 1998- 437: 145−148
179. Tran M. T., Mitchell T.M., Kennedy D. T., Giles J. T. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 2001- 21: 7: 797 -806.
180. Vasquez-Vivar 3, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, and Pritchard KA Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 95: 9220−9225, 1998.
181. Veronique Witko-Sarsat, Miriam Friedlander et al. Advanced oxidation protein products as novel marker of oxidative stress in uremia. Kidney International, 1996, 49, 1304−1313.
182. Viigimaa M, Abina J, Zemtsovskaya G, Tikhaze A, Konovalova G, Kumskova E, Lankin V. Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis. Blood Press.2010 Jun- 19(3):164−8.
183. Violi F., Micheletta F. and Luliano L. Antioxidants and atherosclerosis. Eur. Heart J. Suppl 2002- 4 (Suppl B): B17-B21.
184. Von Eckardsen A., Nofer I.R., Assman G. HDL and atherosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arter. ThrombVasc Biol. 2001- 21: 13−27.
185. Weiss S.T. Cardiovascular effects of environmental tobacco smoke. Circulation. 1996. V. 94. P. 599.
186. Welch G., Upchurch G., Loscalzo J. Hyperhomocyst (e)inemia and atherothrombosis. Ann N Y Acad Sci 1997- 811: 48−58.
187. Williams K.J., K.J. Williams, E.A. Fisher. Oxidation, lipoproteins and atherosclerosis. Curr. Opin. Clin. Nutr. Care. 2005. Vol. 8. P. 139−146.
188. Yamagishi S, Nakamura K, Matsui T. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr Med Chem. 2008- 15(2): 172−7
189. Zhuang XF, Yin CQ, Wang HY, Sun NL. Distinctive-effects of carvedilol in the non-infarct zone: remodeling of the ligated rat heart linked to oxidative stress. J Int Med Res. 2009 Sep-Oct- 37(5): 1354−64.
190. Zweier J.L., Flaherty J. T., Weisfeldt M.L. Direct measurement of free radical generation following reperfusion of i dium.